TargImmune Therapeutics
TargImmune is dedicated to transforming survival for cancer patients through its innovative portfolio of oncology compounds and groundbreaking modular, synthetic, targeted platform technology. Their proprietary Ta:RNA™ platform harnesses the body's immune system to target and destroy cancer cells, offering a multi-pronged approach against solid tumours and metastases. The company aims to significantly improve patient outcomes by developing targeted immunotherapies that can be delivered systemically, reaching distant metastases and addressing a wide range of cancers.
Industries
Nr. of Employees
small (1-50)
TargImmune Therapeutics
Basel, Basel-Stadt, Switzerland, Europe
Products
TAR001
Lead platform-derived clinical candidate that targets tumour cells via an overexpressed receptor to deliver synthetic double-stranded RNA systemically, designed to induce tumour cell death and immune modulation.
TAR002
Second platform-derived nucleic acid therapeutic currently in preclinical development, representing an additional receptor-targeted TAIM-class candidate.
TAR001
Lead platform-derived clinical candidate that targets tumour cells via an overexpressed receptor to deliver synthetic double-stranded RNA systemically, designed to induce tumour cell death and immune modulation.
TAR002
Second platform-derived nucleic acid therapeutic currently in preclinical development, representing an additional receptor-targeted TAIM-class candidate.
Expertise Areas
- Targeted nucleic acid therapeutics
- Oncology drug development (solid tumours)
- Nanoparticle-mediated targeted delivery
- Preclinical GLP toxicology and safety assessment
Key Technologies
- Synthetic nanoparticle delivery
- Double-stranded RNA therapeutics (dsRNA)
- Receptor-targeted ligand/moiety exchange (modular targeting)
- Systemic nucleic acid delivery